🏆Vocxi Health Wins the Silicon Valley Regional Startup World Cup!

GSD Venture Studios
May 4
3 min read

By Gary Fowler

From Mayo Clinic insights to AI-powered breath diagnostics, this GSD Venture Studios startup is breathing new life into early cancer detection.

🌍 Discover the GSD SuperScaler Program🚀 Fueling Global Startups with AI, Quantum, and World-Class Mentorship

Silicon Valley, May 1, 2025 — In a thrilling celebration of innovation and impact, Vocxi Health, a pioneering diagnostic startup, has officially claimed the Startup World Cup’s Silicon Valley Regional Title. As a standout company from Cohort 19 of GSD Venture Studios’ SuperScaler Program, Vocxi is gaining serious momentum as a global leader in noninvasive breath-based cancer diagnostics.

“We’re honored and energized by this recognition,” said Ping Yeh, CEO of Vocxi Health. “This isn’t just a win for our company — it’s a win for every patient who deserves faster, safer answers about their health.”

🔬 The Origin of a Life-Saving Idea

Vocxi’s roots trace back more than a decade, when Greg Sherwood, now CTO of Vocxi Health, was embedded at the Mayo Clinic on assignment from a global medical device leader. There, he shadowed pulmonologists and witnessed firsthand the anxiety and inefficiencies in lung cancer screening.

He discovered a shocking truth: 70% of patients with nodules undergo years of repeated CT scans before a definitive diagnosis, often exposing them to radiation and delays. Most biopsies turn out to be unnecessary. Yet for the 4% that are malignant, every month counts.

This sparked a question that changed everything:

“What if we could detect cancer simply by analyzing a patient’s breath?”

🧪 From Concept to Clinical: The Science of MyBreathPrint®

Sherwood’s research led him to volatile organic compounds (VOCs) — chemical traces in exhaled breath that dogs have been trained to detect in cancer patients. Inspired, he began developing a sensor system as sensitive as a dog’s nose, built on cutting-edge chemistry, material science, and engineering.

In 2014, he met Greg Peterson, a leader in innovation from a top-tier research university. The two formed a cross-disciplinary team that included experts in:

Animal science
Mechanical engineering
Surgical instrumentation
Soil and chemical sensing

Over eight years, the team refined their system, and by 2018 they were conducting human clinical trials. In 2022, Vocxi Health was born — bringing together brilliant minds from both research and industry to commercialize their core innovation: MyBreathPrint®.

💡 MyBreathPrint®: How It Works

Imagine a world where a patient simply breathes into a device, and the sensor detects molecular signatures of disease. That’s the promise of MyBreathPrint® — a proprietary breath analysis platform built to:

✅ Detect lung cancer with unprecedented accuracy

✅ Avoid invasive biopsies unless truly necessary

✅ Deliver results in minutes instead of months

MyBreathPrint® is more than a diagnostic tool. It’s a paradigm shift in how we think about cancer detection.

🌐 The GSD Venture Studios Advantage

Vocxi’s journey from lab to global stage was accelerated by GSD Venture Studios, a venture builder known for scaling deep tech companies worldwide.

Through its SuperScaler Program, GSD provided Vocxi with:

Strategic advisory support from top global mentors
Access to PR and investor networks
AI and commercialization expertise
Global positioning and storytelling guidance

“GSD Venture Studios has been instrumental in helping us define our go-to-market strategy and attract global attention,” said Ping Yeh, CEO of Vocxi.

🏆 What’s Next for Vocxi Health?

After taking home the Startup World Cup Silicon Valley crown, Vocxi now advances to the global grand finale in San Francisco — where they’ll pitch against champions from more than 50 countries for the $1 million investment prize.

But for Vocxi, the real prize is impact.

“Every breath holds a story,” says Sherwood. “We’re here to listen — and to save lives.”

🙌 Congratulations to the Vocxi Team

With their roots in deep science, medical empathy, and global startup excellence, Vocxi is poised to revolutionize how we screen, diagnose, and ultimately save millions of lives from lung cancer and beyond.

🚀 About Vocxi Health

Vocxi Health is a diagnostic startup transforming breath into data for early, accurate, noninvasive cancer detection. Born from collaboration between a global medical device company and a world-class research hospital, Vocxi’s MyBreathPrint® platform uses advanced VOC sensing technology to detect disease with unmatched ease and accuracy.

Visit VocxiHealth.com

🔗 About GSD Venture Studios

Founded by Gary Fowler, GSD Venture Studios helps AI and deep tech startups go global from day one. With over 1200 podcast episodes, 7 books, and 600+ published articles, GSD is one of the world’s most prolific forces in global startup acceleration. Services include the GSD SuperScaler Program, GSD Advisory, GSD Fund, and GSD Reach, a powerful PR firm for tech founders.